Evidence map›Paper›PMID 39199588›Full record

ArticleCancers2024

Analysis by TeloView

Hans Knecht, Nathalie Johnson, Marc N Bienz, Pierre Brousset, Lorenzo Memeo, Yulia Shifrin, Asieh Alikhah, Sherif F Louis, Sabine Mai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hans KnechtDivision of Hematology, Jewish General Hospital, McGill University, Montréal, QC H3A 0G4, Canada.ORCID 0000-0002-7909-7866
Nathalie JohnsonDivision of Hematology, Jewish General Hospital, McGill University, Montréal, QC H3A 0G4, Canada.
Marc N BienzDivision of Hematology, Jewish General Hospital, McGill University, Montréal, QC H3A 0G4, Canada.ORCID 0000-0002-6683-5348
Pierre BroussetToulouse Cancer Center, Université de Toulouse, 31000 Toulouse, France.
Lorenzo MemeoPathology Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, 95029 Viagrande, Italy.ORCID 0000-0003-4251-7203
Yulia ShifrinTelo Genomics Corp., Toronto ON M5G 1L7, Canada.
Asieh AlikhahTelo Genomics Corp., Toronto ON M5G 1L7, Canada.
Sherif F LouisTelo Genomics Corp., Toronto ON M5G 1L7, Canada.
Sabine MaiDepartment of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB R3T 2N, Canada.ORCID 0000-0002-5797-2201

Funding

Telo Genomics, Toronto, Ontario, Canada N/A
6 · The paper itself

Abstract

Classic Hodgkin's lymphoma (cHL) is a curable cancer with a disease-free survival rate of over 10 years. Over 80% of diagnosed patients respond favorably to first-line chemotherapy, but few biomarkers exist that can predict the 15-20% of patients who experience refractory or early relapsed disease. To date, the identification of patients who will not respond to first-line therapy based on disease staging and traditional clinical risk factor analysis is still not possible. Three-dimensional (3D) telomere analysis using the TeloView

Indexed as

3D telomere profilingABVD therapyHodgkin lymphomapredictive modelprognostic biomarkerrelapse

Identifiers

PMID39199588
PMCPMC11352807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.